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ABSTRACT
RNA interference (RNAi) is a crucial antiviral defense
mechanism in insects, including the major mosquito
species that transmit important human viruses. To
counteract the potent antiviral RNAi pathway, insect
viruses encode RNAi suppressors. However, whether
mosquito-specific viruses suppress RNAi remains
unclear. We therefore set out to study RNAi sup-
pression by Culex Y virus (CYV), a mosquito-specific
virus of the Birnaviridae family that was recently iso-
lated from Culex pipiens mosquitoes. We found that
the Culex RNAi machinery processes CYV double-
stranded RNA (dsRNA) into viral small interfering
RNAs (vsiRNAs). Furthermore, we show that RNAi
is suppressed in CYV-infected cells and that the vi-
ral VP3 protein is responsible for RNAi antagonism.
We demonstrate that VP3 can functionally replace
B2, the well-characterized RNAi suppressor of Flock
House virus. VP3 was found to bind long dsRNA as
well as siRNAs and interfered with Dicer-2-mediated
cleavage of long dsRNA into siRNAs. Slicing of tar-
get RNAs by pre-assembled RNA-induced silencing
complexes was not affected by VP3. Finally, we show
that the RNAi-suppressive activity of VP3 is con-
served in Drosophila X virus, a birnavirus that per-
sistently infects Drosophila cell cultures. Together,
our data indicate that mosquito-specific viruses may
encode RNAi antagonists to suppress antiviral RNAi.
INTRODUCTION
RNA interference (RNAi) is a cellular mechanism that reg-
ulates gene expression in a broad range of eukaryotes. In
plants (1), insects (2–4), nematodes (5,6), and fungi (7),
the RNAi pathway is a crucial antiviral defense mecha-
nism (reviewed in (8,9)). The antiviral potential of RNAi
in vertebrates has only recently been demonstrated (10,11).
For insects, the antiviral RNAi pathway is most extensively
studied in Drosophila melanogaster. The current model for
antiviral RNAi in Drosophila is that virus-derived double-
stranded RNA (dsRNA) is processed by Dicer-2 (Dcr-2)
into viral small interferingRNA (vsiRNA) duplexes that as-
sociate with Argonaute-2 (AGO2) within the RNA-induced
silencing complex (RISC) (9). One strand of the vsiRNA
duplex is retained in RISC to guide the identification and
AGO2-mediated cleavage (slicing) of complementary viral
RNAs (9). The detection of vsiRNAs during infections of
Drosophila cell lines and adult flies supports this model
(12,13). Moreover, the hypersensitivity ofDrosophilaRNAi
pathwaymutants to virus infections confirms the important
role of RNAi in antiviral defense (2–4,14–19).
Insect viruses encode viral suppressors of RNAi (VSRs)
to counteract the antiviral RNAi pathway. For example,
the Flock House virus (FHV) B2 and Drosophila C virus
(DCV) 1A proteins bind and shield long dsRNA fromDcr-
2 cleavage (2,5,20,21). FHV B2 additionally binds siRNA
duplexes, which inhibits their loading into RISC (5,20). The
1A protein of Cricket paralysis virus (CrPV) and viral pro-
tein 1 (VP1) of Nora virus were recently shown to inhibit
AGO2 Slicer activity (22,23). In general, RNAi suppres-
sor proteins of different virus families that target the same
step in the RNAi pathway do not share sequence identity or
structural conservation. Thus, insect viruses independently
evolved a diverse set of RNAi antagonists that suppress the
antiviral RNAi pathway by distinct mechanisms.
Mosquitoes are vectors for the transmission of
arthropod-borne (arbo) viruses that can cause serious
disease in humans, such as Dengue virus (DENV), West
Nile virus (WNV) and Chikungunya virus (24). In addition,
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mosquitoes are hosts to a diverse array of mosquito-specific
viruses that are not transmitted to vertebrates (25–29).
These viruses do not cause human disease, but they are of
interest with regard to human health. Mosquito-specific
viruses infect mosquito species that act as important
vectors for human arbovirus transmission. Activation and
suppression of antiviral immune pathways by mosquito-
specific viruses may affect the ability of a vector mosquito
to transmit co-infecting arboviruses. Currently, however,
not much is known about the interactions between the
mosquito’s immune system and the different classes of
mosquito viruses.
As is observed in virus infections ofDrosophila, vsiRNAs
are detected in mosquitoes and mosquito cell lines infected
with arboviruses and mosquito-specific viruses (12,13). In
addition, knockdown of RNAi pathway components in
mosquitoes results in higher virus titers after infection with
different arboviruses (30–32). These results show that, also
in mosquitoes, the RNAi pathway serves as an important
antiviral defense mechanism. Despite the antiviral activ-
ity of the mosquito RNAi pathway against a broad range
of viruses, reports on VSR activity in viruses that infect
mosquitoes are limited. VSRs have thus far only been
identified in a few arboviruses from the genera Alphan-
odavirus (Nodaviridae family) and Flavivirus (Flaviviridae
family) (21,33–35). Whether mosquito-specific viruses sup-
press RNAi is unknown.
Nodamura virus (NoV), like FHV a member of the
Alphanodavirus genus, was first isolated from Culex tri-
taeniorhynchus mosquitoes in Japan (36). Successful ex-
perimental infections in vertebrates, and the detection of
neutralizing antibodies in pigs, suggest that NoV is a
mosquito-transmitted arbovirus (37). The B2 protein of
NoV, like FHV B2, inhibits RNAi by binding long dsRNA
as well as siRNA duplexes (21,33). More recently, the non-
coding subgenomic flavivirusRNAs (sfRNAs) ofWNVand
DENV, two arboviruses from the Flavivirus genus, were
shown to suppress RNAi (34). sfRNAs are abundantly pro-
duced during flavivirus infection and result from incomplete
degradation of the genomic RNA (38). Probably because of
their stem-loop structure, sfRNA molecules compete with
Dicer substrates, thereby decreasing Dicer activity. DENV
non-structural protein 4B (NS4B) was suggested to inhibit
Dicer function through an undefined mechanism (35).
The identification and characterization of viral immune
antagonists may provide important insights into the mech-
anisms, components and regulators of immune pathways.
For example, the observation that two unrelated RNA
viruses encode Slicer antagonists indicates that slicing of
viral target RNAs is an important aspect of the antiviral
RNAi response (22,23). To begin to understand the diver-
sity of RNAi-suppressive activities in mosquito viruses, we
set out to study RNAi suppression by the mosquito-specific
Culex Y virus (CYV). CYV is a bisegmented dsRNA
virus from the Entomobirnavirus genus within the Birnaviri-
dae family that was recently isolated from Culex pipiens
mosquitoes in Germany (27). Isolation of the highly related
Espirito Santo virus and Mosquito X virus in Brazil and
China, respectively, indicates that these entomobirnaviruses
are widely distributed in nature (28,29).
Here, we demonstrate that CYV is a target of the Culex
RNAi machinery. Furthermore, we show that CYV and
Drosophila X virus (DXV), like CYV a member of the En-
tomobirnavirus genus, suppress the RNAi pathway during
infection. The entomobirnavirus RNAi suppressor activity
was mapped to VP3 and we show that the VP3 proteins can
rescue the replication of a B2-deficient FHV RNA1 repli-
con. Finally, we demonstrate that the VP3 proteins bind
long dsRNA as well as siRNAs and that they inhibit the
production of siRNAs by Dcr-2. To our knowledge, we de-
scribe the first VSR of a mosquito-specific virus.
MATERIALS AND METHODS
Cells and viruses
Drosophila melanogaster S2, Culex quinquefasciatus Hsu
and Culex tarsalis CT cells were cultured in Schneider’s
Drosophila medium (Life Technologies) at 25◦C (S2 cells)
or 28◦C (Hsu and CT cells). The medium was supple-
mented with 10% heat-inactivated fetal bovine serum (FBS;
PAA Laboratories), 50 U/ml penicillin and 50 g/ml strep-
tomycin (pen/strep; Life Technologies). Aedes albopictus
U4.4 cells were maintained at 28◦C in Leibovitz’s L-15
medium (Life Technologies) supplemented with 10% heat-
inactivated FBS, 2% tryptose phosphate broth (Sigma-
Aldrich), 1× MEM non-essential amino acids (Life Tech-
nologies) and pen/strep. CYV and DXV were propagated
in S2 cells.
Plasmids, radioactively-labeled probes, recombinant proteins
and western blot analysis
The cloning and origin of plasmids, the production of
radioactively-labeled probes, the purification of recombi-
nant proteins and western blot analysis are described in the
Supplementary Data.
Massive parallel sequencing of small RNAs
RNA was isolated from CYV-infected CT cells at 3
days post-infection using Isol-RNA Lysis Reagent (5
PRIME) and 30 g of the RNA was separated on a 15%
polyacrylamide/7M urea/0.5× TBE gel. The 19- to 33-nt
small RNA fraction was cut from gel using 32P end-labeled
RNA oligos as size markers. The RNA was eluted in 0.3 M
of NaOAc, precipitated in 100% EtOH and dissolved in 10
l of H2O. The small RNA library was prepared with the
TruSeq Small RNA Sample Preparation Kit (Illumina) ac-
cording to the manufacturer’s instructions. After amplifica-
tion, the library was separated on a 6% polyacrylamide/1×
TBE gel. The PCR product corresponding to the amplified
small RNAs was cut from gel, eluted in 0.3 M of NaOAc,
precipitated in 100% EtOH in the presence of 20 g of
glycogen and reconstituted in 10l of 10mMTris-HCl. The
library was sequenced on an Illumina HiSeq 2500 by Base-
clear (www.baseclear.nl). FASTQ sequence reads were gen-
erated with the Illumina Casava pipeline (version 1.8.3) and
initial quality assessment was performed by Baseclear using
in-house scripts and the FASTQC quality control tool (ver-
sion 0.10.0). FASTQ sequence reads that passed this quality
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control were deposited in the SequenceReadArchive (SRA)
under accession number SRP041409.
The sequence data were analyzed with Galaxy (39).
Sequence reads were clipped from the adapter sequence
(TruSeq 3′ adapter index #8) and mapped with Bowtie (ver-
sion 1.1.2) (40) to the CYV reference genome (GenBank ac-
cession numbers: JQ659254 and JQ659255 for genome seg-
ments A and B, respectively). A size profile of the viral small
RNAswas obtained from all reads that mapped to the CYV
genome with a maximum of one mismatch. The 5′ ends of
the 21-nt CYV-mapping reads were plotted onto the viral
genome to analyze the genome distribution of the vsiRNAs.
RNAi reporter assays
RNAi reporter assays in S2 cells were performed as de-
scribed previously (41). In dsRNA-induced RNAi reporter
assays with individual proteins, S2 cells in 96-well plates
were transfected with 12.5 ng of pMT-FLuc, 3 ng of pMT-
RLuc and 50 ng of an expression plasmid for one of the
viral proteins using Effectene Transfection Reagent (QIA-
GEN). Two days after transfection, 1.4 ng/l of dsRNA
was added to the culture supernatant. Expression of the lu-
ciferase reporters was induced the same day with 0.5 mM
of CuSO4. Luciferase activities were measured the follow-
ing day with the Dual-Luciferase Reporter Assay System
(Promega). The siRNA-induced RNAi reporter assays with
individual proteins were performed as two variants. One of
these variants was identical to the dsRNA-induced RNAi
reporter assay, except that dsRNA feeding was omitted and
siRNAs (2 pmol) were co-transfected with the plasmids. In
the other variant, S2 cells in 24-well plates were transfected
with 100 ng of pCoBlast (Life Technologies) and 300 ng of
an expression plasmid for one of the viral proteins. Two days
after transfection, the cells were transferred to 96-well plates
and the culture medium was supplemented with 25 g/ml
of blasticidin S (Life Technologies) to select for cells that
express the viral proteins. The cells were transfected the fol-
lowing day with 12.5 ng of pMT-FLuc, 3 ng of pMT-RLuc,
2 pmol of siRNAs and 50 ng of a carrier plasmid. The re-
porters were induced the next day and luciferase activities
were measured one day after induction. In RNAi reporter
assays with infected cells, mock- and CYV-infected S2 cells
in 96-well plates were transfected 3 days post-infection with
12.5 ng of pMT-FLuc, 3 ng of pMT-RLuc and either 10
ng of dsRNA or 2 pmol of siRNAs. Expression of the lu-
ciferase reporters was induced the same day and luciferase
activities were measured 4 days post-infection. RNAi re-
porter assays with DXV-infected S2 cells were performed
in a similar fashion, except that transfection and induction
were performed at 6 h and 1 day post-infection, respectively.
Luciferase activities were measured 2 days post-infection.
For RNAi reporter assays in CT cells, mock- and CYV-
infected CT cells in 24-well plates were transfected 2 days
post-infection with 250 ng of pAc-FLuc, 250 ng of pAc-
RLuc and 10 ng of dsRNA using X-tremeGENEHPDNA
Transfection Reagent (Roche). Luciferase activities were
measured 2 days post-infection.
FHV RNA1 replicon assay
S2 cells in a 24-well plate were transfected with 100 ng of
the wild-type or B2 FHV RNA1 replicons and 300 ng of
an expression plasmid for one of the viral proteins using
Effectene Transfection Reagent. Transcription of the FHV
RNA1 replicons was induced two days after transfection
by the addition of 0.5 mM of CuSO4 to the culture super-
natant. The next day, RNA was isolated from the cells us-
ing Isol-RNA Lysis Reagent. The RNA was treated with
DNase I (Life Technologies) and converted to cDNA us-
ing TaqMan Reverse Transcription Reagents (Life Tech-
nologies) and either FHV RNA1-specific primer T7-FHV-
RNA1-R1 or RpL32-specific primer RpL32-R1 (Supple-
mentary Table S1). The cDNA samples were then used in
quantitative PCRs (qPCRs) on a LightCycler 480 (Roche)
using GoTaq qPCR Master Mix (Promega) and either
primers T7-F1 and FHV-RNA1-F3 (FHV RNA1 qPCR)
or primers RpL32-R1 andRpL32-F1 (RpL32 qPCR) (Sup-
plementary Table S1). The FHV RNA1 data were normal-
ized to RpL32.
Dicer assays, Slicer assays and electrophoretic mobility shift
assays (EMSAs)
Dicer assays, Slicer assays and EMSAs with purified recom-
binant proteins and radioactively-labeled probes were done
essentially as described previously (2,23,42). Dicer assays
were performed in 12-l reactions with recombinant pro-
teins, 4 l of cell extract and 5 ng of radioactively-labeled
126-nt dsRNA. For Dicer assays in mock- and CYV-
infected cell extracts, recombinant proteins were omitted
from the reaction. Dicer assays in S2 cell extracts were in-
cubated for 3 h at 25◦C and those in U4.4, CT and Hsu cell
extracts at 28◦C. The reactions were treated with proteinase
K (Life Technologies), extracted with phenol/chloroform,
precipitated and analyzed on 12% denaturing polyacry-
lamide gels.
Slicer assays were done in 11-l reactions that contained
5 l of D. melanogaster embryo lysate and 50 nM of siR-
NAs. The siRNA duplexes were first incubated in the em-
bryo lysates for 30 min at 25◦C to allow assembly of mature
RISC. Recombinant proteins were then added and the in-
cubation was continued for another 30 min before the reac-
tions were supplemented with the radioactive 5′ cap-labeled
492-bp target RNA. The reactions were incubated for an
additional 2 h at 25◦C before they were treated with pro-
teinase K, extracted with phenol/chloroform, precipitated
and analyzed on an 8% denaturing polyacrylamide gel.
EMSAs were performed in 16-l reactions with recombi-
nant proteins and either 5 ng of radioactively-labeled 126-nt
dsRNA or 1 nM of radioactively-labeled 21-nt siRNA, 21-
nt dsRNA, 19-nt dsRNA, 23-nt microRNA (miRNA) or
21-nt dsDNA duplexes. The reactions were incubated for 1
h at room temperature and analyzed on 6% (126-nt dsRNA)
and 8% (small RNA and DNA duplexes) native polyacry-
lamide gels.
Dicer assays, Slicer assays and EMSAs were visualized
by autoradiography using KODAKBioMax XAR films. To
quantify the fraction bound probe in the EMSAs, the ra-
dioactive signals were captured with a Molecular Imager
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FX (Bio-Rad) and quantified with ImageJ (version 1.47k)
(43).
Statistics
IBM SPSS Statistics (version 20) was used to statistically
analyze the data. Statistical significance was addressed by
applying an unpaired t-test or, in the case of multiple com-
parisons, a one-way ANOVA followed by a Dunnett’s post
hoc test.
RESULTS
CYV is a target of the Culex RNAi machinery
The identification of vsiRNAs in infections with DXV,
Drosophila birnavirus and Mosquito X virus as well
as the enhanced sensitivity of R2D2 and AGO2 mutant
flies to DXV infection indicates that entomobirnaviruses
are a target of the antiviral RNAi machinery in insects
(14,29,44,45). To investigate whether the Culex RNAi ma-
chinery targets CYV, we first analyzed whether CYV effi-
ciently replicates in C. quinquefasciatus Hsu and C. tarsalis
CT cells. Since Hsu cells were resistant to CYV (data not
shown), we performed massive parallel sequencing of the
small RNAs in CYV-infected CT cells. The small RNAs
were mapped to the viral genome allowing one mismatch
during alignment to account for genome variants that re-
sult from the relatively high error rates generally observed
for viral RNA-dependent RNA polymerases. We detected
10 260 120 small RNAs that mapped to the viral genome.
These viral small RNAs were almost exclusively 21 nt in
length (Figure 1A), a hallmark of siRNAs that are gener-
ated by Dcr-2. The majority of the 21-nt vsiRNAs (9 001
430 in total; 6 997 378 and 2 004 052 for segments A and
B, respectively) mapped across the entire length of the viral
genome (Figure 1B). In addition, we noted a clear vsiRNA
hotspot on the 3′ end of the (−) strand of both genome
segments (Figure 1B). Overall, however, the vsiRNAs did
not display a clear strand bias, as they mapped in similar
numbers to the sense strand (46% for segment A and 47%
for segment B) and antisense strand (54% for segment A
and 53% for segment B) (Figure 1B). These results indicate
that CYV is exposed to an RNAi response in Culex cells
and they suggest that the CYV dsRNA genome is the ma-
jor Dcr-2 substrate for vsiRNA production. Similar results
were obtained when restricting the analyses to the 9 875 389
small RNAs that mapped to the viral genome without mis-
matches (data not shown).
The CYV VP3 protein suppresses RNAi
Since CYV is a target of the antiviral RNAi machinery in
Culex, we deemed it likely that the virus would encode a
VSR. We therefore used well-established reporter assays to
determine whether CYV counteracts RNAi (41). In these
assays, the effect of virus infection or expression of indi-
vidual viral proteins on RNAi-mediated silencing of a fire-
fly luciferase (FLuc) reporter is monitored. We first deter-
mined whether RNAi is suppressed in cells that are infected
with CYV. To this end, we measured luciferase activities in
mock- and CYV-infected cells that were co-transfected with
Figure 1. CYV is targeted by the Culex RNAi machinery. (A) Size pro-
file of viral small RNAs in CYV-infected CT cells. The small RNAs were
mapped to the CYV genome allowing one mismatch. (B) Distribution of
the vsiRNAs over the CYV genome. The 21-nt vsiRNAs in CYV-infected
CT cells were aligned to CYV genome segments A (upper panel) and B
(lower panel). Small RNAs that map to the (+) strand of the viral genome
are shown in red and those that map to the (−) strand in blue.
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the FLuc reporter plasmid and 113-nt in vitro transcribed
FLuc dsRNA. A Renilla luciferase (RLuc) reporter plas-
mid was included as a normalization control. As expected,
in mock-infectedDrosophila S2 cells, the FLuc reporter was
efficiently silenced (∼600-fold) by dsRNA treatment (Fig-
ure 2A, left panel). However, dsRNA-mediated silencing of
the FLuc reporter was strongly suppressed (to ∼6-fold; P
= 0.002) in CYV-infected S2 cells (Figure 2A, left panel). A
comparable reduction of FLuc silencing (from∼300-fold to
∼20-fold; P < 0.001) was observed in CYV-infected Culex
CT cells (Figure 2A, right panel). CYV infection also sup-
pressed silencing of the FLuc reporter (from ∼15-fold to
∼3-fold;P= 0.025) when we induced RNAi with 21-nt syn-
thetic siRNA duplexes (Figure 2B). These data show that
CYV infection inhibits RNAi induced by dsRNA as well as
siRNAs.
To identify the viral proteins responsible for CYV-
mediated RNAi suppression, we generated expression con-
structs for the five proteins (VP1 to VP5) that are predicted
to be encoded by the CYV genome (Figure 3A). Expres-
sion of all five proteins in transfected cells was confirmed by
western blot analysis (Figure 3B). We then tested the indi-
vidual viral proteins for VSR activity in our RNAi reporter
assays. Cells were co-transfected with the FLuc and RLuc
reporter plasmids and an expression plasmid for one of the
viral proteins. The FLuc reporter was silenced by dsRNA
feeding two days after transfection to allow expression of
the viral proteins before the induction of RNAi. Of the five
viral proteins, only VP3 suppressed silencing of the FLuc re-
porter (from ∼15-fold to background levels; P < 0.001) to
a similar extent as the positive control CrPV 1A (22) (Fig-
ure 3C). However, VP3 did not inhibit silencing of the FLuc
reporter whenRNAi was induced by co-transfection of siR-
NAs along with the luciferase and VP3 expression plasmids
(Figure 3D). This is in contrast to the AGO2 antagonists
Nora virus VP1 (P = 0.002) and CrPV 1A that effectively
suppress siRNA-induced RNAi in reporter assays (Figure
3D and (22,23)). The inability of VP3 to suppress siRNA-
induced RNAi under these conditions seems at odds with
the reduced efficiency of siRNA-induced RNAi in CYV-
infected cells (Figure 2B). However, in Figure 2B, the cells
were infected three days prior to transfection of the siR-
NAs and reporter plasmids, whereas in Figure 3D, the siR-
NAs were co-transfected along with the luciferase and VP3
expression plasmids. Most likely, the siRNAs are incorpo-
rated into RISC before VP3 is expressed at sufficiently high
levels in the latter case. Indeed, VP3 was able to suppress si-
lencing of the FLuc reporter (from ∼27-fold to ∼13-fold;
P < 0.001) when the VP3 expression plasmid was trans-
fected three days before transfection of the siRNAs and re-
porter plasmids (Figure 3E). These data suggest that VP3
suppresses the RNAi pathway at a step that precedes target
cleavage by AGO2.
The RNAi pathway shares basic features with the
miRNA pathway. Both pathways depend on Dicer proteins
for the generation of small RNAs that guide the recognition
and silencing of complementary RNAs by Argonaute pro-
teins. The Dicer and Argonaute proteins in the RNAi and
miRNA pathways are, however, different. The RNAi path-
way depends onDcr-2 andAGO2 for small RNAbiogenesis
and function, whereas the miRNA pathway predominantly
depends on Dcr-1 and AGO1. We observed that CYV VP3
did not interfere with miRNA biogenesis and function (see
Supplementary Data), indicating that VP3 specifically in-
hibits the RNAi pathway.
The VSR activity of VP3 is conserved in DXV
Having identified CYV VP3 as a suppressor of RNAi,
we analyzed whether the VSR activity of this protein
is conserved in DXV, an entomobirnavirus that infects
Drosophila. To this end, we first studied RNAi suppres-
sion in DXV-infected cells. As observed for CYV, dsRNA-
mediated silencing of the FLuc reporter was strongly sup-
pressed (from ∼1300-fold to ∼150-fold; P = 0.005) in S2
cells infected with DXV (Figure 4A). We then tested the
DXV VP3 protein for VSR activity. DXV VP3 suppressed
silencing of the FLuc reporter (from ∼15-fold to back-
ground levels; P < 0.001) when RNAi was induced by
dsRNA feeding two days after transfection of the luciferase
and VP3 expression plasmids (Figure 4B). In addition,
DXV VP3 suppressed silencing of the FLuc reporter (from
∼23-fold to ∼9-fold; P < 0.001) when we induced RNAi
by co-transfection of siRNAs along with the luciferase and
VP3 expression plasmids (Figure 4C), and (from ∼19-fold
to ∼3-fold; P< 0.001) when the siRNAs and reporter plas-
mids were transfected three days after transfection of the
VP3 expression plasmid (Figure 4D). These results indicate
that the VSR activity of VP3 is conserved during entomo-
birnavirus evolution.
CYV and DXV VP3 can functionally replace FHV B2
Our data indicate that the CYV and DXV VP3 proteins are
functional RNAi suppressors. Reverse genetics systems to
engineer entomobirnaviruses are not yet available, preclud-
ing us to study the importance of VP3’s VSR activity in
an authentic infection. As an alternative, we tested whether
the entomobirnavirus VP3 proteins can functionally re-
place B2, the well-established VSR of FHV (5,20,21,46).
The bisegmented FHV genome consists of genomic RNA1
and RNA2, which encode the RNA-dependent RNA poly-
merase (protein A) and capsid proteins, respectively. In ad-
dition to encoding the RNA-dependent RNA polymerase,
RNA1 gives rise to subgenomic RNA3, which encodes the
RNAi suppressor protein B2. FHVRNA1 can replicate au-
tonomously, but its replication in RNAi competent insect
cells is severely restricted in the absence of B2 (4,46). The
replication defect of B2-deficient FHV RNA1 is attributed
to its inability to suppress the antiviral RNAi response,
since its replication is restored by suppression of the RNAi
pathway (4,46).
We used an FHV RNA1B2 replicon to determine
whether the CYV and DXV VP3 proteins can rescue its
replication. This FHV RNA1B2 replicon contains two
point mutations in the B2 coding region (Figure 5A). These
pointmutations disrupt B2, but they do not affect the amino
acid sequence of the RNA-dependent RNA polymerase
(47). We co-transfected cells with the FHV RNA1B2
replicon and one of the VP3 expression plasmids and moni-
tored RNA1 accumulation. As predicted, FHVRNA1B2
was severely impaired when compared to wild-type FHV
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Figure 2. RNAi is suppressed during CYV infection. (A) dsRNA-induced RNAi reporter assays in infectedDrosophila S2 (left panel) and Culex CT (right
panel) cells. Firefly (FLuc) andRenilla (RLuc) luciferase expression plasmids were transfected together with non-specific control (dsCtrl) or FLuc (dsFLuc)
dsRNA into mock- and CYV-infected cells. Luciferase activities were measured and FLuc counts were normalized to RLuc counts. The data are presented
as fold silencing relative to dsCtrl. (B) siRNA-induced RNAi reporter assay in infected S2 cells. The experiment was performed as in (A), except that
RNAi was induced by co-transfection of non-specific control (siCtrl) or FLuc (siFLuc) siRNAs along with the luciferase expression plasmids. The data
are presented as fold silencing relative to siCtrl. Bars and error bars in all panels represent the mean and standard deviation of three independent samples.
RNA1. The RNA1 levels of the B2-deficient replicon only
reached 0.15% of those of the wild-type replicon, a differ-
ence of ∼700-fold. However, replication of the B2-deficient
replicon was enhanced in the presence of our positive con-
trolNora virusVP1 (23) (∼100-fold; to 15%of thewild-type
replicon; P = 0.041), and in the presence of either CYV or
DXV VP3 (∼200-fold; to 34% of the wild-type replicon; P
< 0.001 for both) (Figure 5B). These results show that en-
tomobirnavirus VP3 proteins can functionally replace the
VSR of FHV.
CYV and DXV VP3 inhibit dicing of dsRNA
VSRs of different viruses may target different aspects of
the RNAi machinery, such as Dcr-2-mediated cleavage of
dsRNAand slicing of target RNAs byAGO2. To character-
ize the VSR activity of CYV and DXV VP3 in more detail,
we performed a series of biochemical assays using maltose-
binding protein (MBP)-tagged recombinant proteins puri-
fied from Escherichia coli. We first tested whether the re-
combinant VP3 proteins interfere with dicing of dsRNA,
the initiation phase of the RNAi pathway. We incubated
radioactively-labeled 126-nt dsRNA in D. melanogaster S2,
A. albopictus U4.4, C. quinquefasciatus Hsu and C. tarsalis
CT cell extracts andmonitored its processing into 21-nt siR-
NAs on denaturing polyacrylamide gels. The dsRNA was
efficiently processed into siRNAs in extracts from all cell
types (Figure 6A, lanes 10, 15, 20 and 25). Processing of the
dsRNA was, however, inhibited in a dose-dependent man-
ner by the VP3 proteins of both CYV (Figure 6A, lanes 6–8,
11–13, 16–18 and 21–23) and DXV (Figure 6A, lanes 3–
5), and in the presence of DCV 1A (Figure 6A, lane 1), a
VSR that is known to interact with dsRNA (2). As expected,
MBP alone did not inhibit dsRNA processing (Figure 6A,
lanes 9, 14, 19 and 24). These data indicate that the ento-
mobirnavirus VP3 proteins interfere with siRNA produc-
tion by Dcr-2. Importantly, inhibition of dsRNA cleavage
into siRNAs was also observed in extracts from Drosophila
S2 and Culex CT cells infected with CYV. The dsRNA was
processed in extracts from mock-infected cells (Figure 6B,
lanes 5 and 10), but no dsRNA processing was observed in
extracts from CYV-infected cells (Figure 6B, lanes 1 and 6).
Titration of CYV-infected cell extracts into mock-infected
cell extracts abolished dsRNA processing (Figure 6B, lanes
2–4 and 7–9), which confirms the presence of a Dcr-2 in-
hibitor in CYV-infected cells.
We next tested whether the recombinant VP3 proteins are
capable of interfering with slicing of target RNAs, the effec-
tor phase of theRNAi pathway. For this purpose, a radioac-
tive 5′ cap-labeled target RNA, containing 492 nt of the
FLuc coding sequence, was incubated in D. melanogaster
embryo extracts in the presence of a FLuc-specific siRNA
that triggers its cleavage. Cleavage of the target RNA re-
sults in the production of a 164-nt 5′ cleavage product that
can be visualized on a denaturing polyacrylamide gel. As
expected, cleavage of the target RNA was induced by the
FLuc-specific siRNA (Figure 6C, lane 2), but not by a non-
specific control siRNA (Figure 6C, lane 1). Neither MBP
alone (Figure 6C, lanes 3, 4 and 12), nor the VP3 proteins
of CYV (Figure 6C, lanes 5–7) or DXV (Figure 6C, lanes
8–10), inhibited target RNA cleavage. Complete inhibition
of target RNA cleavage was, however, seen in the presence
of the positive control Nora virus VP1 (Figure 6C, lane 11),
an established VSR that interferes with the Slicer activity
of AGO2 (23). These results demonstrate that the entomo-
birnavirus VP3 proteins do not interfere with target RNA
cleavage by AGO2.
CYV and DXV VP3 possess dsRNA- and siRNA-binding ac-
tivity
Many VSRs employ dsRNA binding as a mechanism to
suppress RNAi (8,9). The ability of the entomobirnavirus
VP3 proteins to inhibit Dcr-2-mediated cleavage of dsRNA
into siRNAs suggests a similar strategy of RNAi sup-
pression. To study whether these proteins indeed pos-
sess dsRNA-binding activity, we performed EMSAs using
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represent the mean and standard deviation of three independent samples.
the recombinant VP3 proteins and different radioactively-
labeled probes.
First, we incubated 126-nt blunt dsRNA with serial
dilutions of the recombinant VP3 proteins and resolved
dsRNA–protein complexes on native polyacrylamide gels.
As expected, incubation of dsRNA with MBP alone (Fig-
ure 7A, lane 15) did not alter its mobility when compared
to the control reaction without recombinant protein (Fig-
ure 7A, lane 16). However, the mobility of the dsRNA was
inhibited in a dose-dependent manner by the VP3 proteins
of both CYV (Figure 7A, lanes 8–14) andDXV (Figure 7A,
lanes 1–7). CYV and DXV VP3 displayed similar affinities
for dsRNA, with dissociation constants of 115.6± 24.5 and
166.1 ± 33.2 nM, respectively (Figure 7A).
The dsRNA-binding activity of the entomobirnavirus
VP3 proteins most likely suppresses RNAi by inhibiting
dsRNAprocessing byDcr-2. However, inhibition of siRNA
production cannot fully explain the RNAi-suppressive ac-
tivity of the VP3 proteins, since they suppressed siRNA-
induced RNAi in our reporter assays (Figures 3E and 4D).
This observation indicates that these proteins target addi-
tional steps of the RNAi pathway, such as loading of siR-
NAs into RISC or slicing of target RNAs by AGO2. Since
our biochemical assays indicate that the VP3 proteins do
not interfere with the AGO2 Slicer activity (Figure 6C), we
tested whether these proteins have the potential to scavenge
siRNAs to prevent their incorporation into RISC. To this
end, we tested serial dilutions of the recombinant VP3 pro-
teins in EMSAs with 21-nt siRNA duplexes containing 2-nt
3′ overhangs. When compared to the control reaction with-
out recombinant protein (Figure 7B, lane 16), the mobility
of the siRNAs was inhibited in a dose-dependent manner
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after incubation with the VP3 proteins of both CYV (Fig-
ure 7B, lanes 8–14) andDXV (Figure 7B, lanes 1–7), but not
after incubation with MBP alone (Figure 7B, lane 15). As
for long dsRNA,CYVandDXVVP3 showed similar affini-
ties for siRNAs, with dissociation constants of 2.6 ± 1.4
and 5.9 ± 1.6 M, respectively (Figure 7B). Interestingly,
both proteins also bound 21- and 19-nt blunt dsRNA, but
only showed weak binding to a 23-nt miRNA duplex (Fig-
ure 7C), consistent with the observation that VP3 does not
inhibit the miRNA pathway (Supplementary Figure S1B).
Binding was RNA-specific, as neither VP3 protein was able
to interact with 21-nt blunt dsDNA (Figure 7C). Taken to-
gether, our data indicate that the entomobirnavirus VP3
proteins are RNAi suppressors that bind both long dsRNA
as well as siRNAs. The dsRNA-binding activity of the VP3
proteins inhibits dsRNA processing into siRNAs and, pre-
sumably, loading of siRNAs into RISC.
DISCUSSION
Viruses employ many different strategies to suppress or
evade the innate and adaptive immune responses of their
hosts. In arthropods, RNAi has antiviral activity against
all major classes of insect viruses, including (+) and (−)
strand RNA, dsRNA and DNA viruses (2–4,14–19,30–32).
Nevertheless, RNAi suppression has thus far not been de-
tected in infections with dsRNA viruses. How widespread
viral RNAi antagonism is among different classes of
viruses remains unclear. Here, we show that the antiviral
RNAi pathway is inhibited during infections withmosquito
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and Drosophila dsRNA viruses from the Entomobirnavirus
genus (Birnaviridae family).
We mapped the VSR activity to VP3, a multifunctional
protein that is involved in many aspects of the viral replica-
tion cycle. Most of our knowledge on the role of VP3 in bir-
navirus replication is derived from experiments with Infec-
tious bursal disease virus (IBDV) and Infectious pancreatic
necrosis virus (IPNV), members of the genera Avibirnavirus
andAquabirnavirus, respectively. The IBDV and IPNVVP3
proteins act as scaffolds during capsid assembly by inter-
acting with the viral genome as well as with the viral VP1
(RNA-dependent RNA polymerase), pVP2 (capsid precur-
sor) and other VP3 proteins (48–52). Our data reveal yet
another function of VP3. We demonstrate that the ento-
mobirnavirus VP3 proteins possess dsRNA- and siRNA-
binding activity and inhibitDcr-2-mediated siRNAproduc-
tion. Importantly, the entomobirnavirus VP3 proteins have
no detectable homology to the VP3 proteins of viruses from
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the other Birnaviridae genera, nor could we identify known
nucleic acid-binding motifs using online domain prediction
programs. Whether entomobirnavirus VP3 has structural
similarity to other dsRNA-binding proteins or whether it
uses a novel protein fold for dsRNA binding is an open
question for future investigation.
In principle, any dsRNA-binding protein has the poten-
tial to inhibit RNAi when overexpressed. Even a dsRNA-
binding protein from E. coli, a species that is not targeted
by an RNAi response, is able to suppress RNAi under over-
expression conditions (53). It has been shown previously
that the IBDV, IPNV and DXV VP3 proteins have the ca-
pacity to suppress RNAi (54). However, these studies were
done in a heterologous system and the in vivo relevance in
a relevant host remained unclear. Our study now provides
evidence that both CYV and DXV infections suppress the
RNAi response in insect cells and that their VP3 proteins
are bona fide RNAi suppressors that rescue replication of a
VSR-defective FHV RNA1 replicon.
dsRNA is an important activator of innate immune path-
ways, such as the interferon response in vertebrates and
antiviral RNAi in invertebrates. To avoid recognition by
the host’s immune system, viruses have evolved different
mechanisms to shield their dsRNA. The genomes of most
dsRNA viruses, for example, are replicated in specialized
viral cores that encapsulate the dsRNA genome through-
out the viral replication cycle (55). These viral cores are
common among dsRNA viruses, but they are absent from
birnaviruses. Instead, studies with IBDV and IPNV have
shown that birnaviruses form ribonucleoprotein (RNP)
complexes consisting of the dsRNA genome and the VP1
and VP3 proteins (56,57). Since VP3 binds homogenously
along the dsRNA genome, the RNP complexes are thought
to prevent the activation of cellular immune pathways. Our
observation that the VP3 proteins of CYV andDXV inhibit
RNAi by dsRNA binding supports this hypothesis. Ento-
mobirnaviruses most likely form similar RNP complexes
that shield the viral genome from the antiviral activity of the
RNAi pathway. Nevertheless, we found that vsiRNAs, de-
rived from the viral genome, are produced in CYV-infected
cells. Moreover, vsiRNAs were previously detected in cells
infected with DXV, Drosophila birnavirus andMosquito X
virus (29,44,45). These data imply that some of the ento-
mobirnaviral dsRNA is accessible for Dcr-2. The observa-
tion that dsRNA viruses from the Totiviridae and Reoviri-
dae families are also prone to an RNAi response shows that
the protection of dsRNA by other dsRNA viruses is incom-
plete as well (44,58,59). By RNP complex formation, VP3
probably limits the accessibility of the viral genome forDcr-
2, but it cannot prevent that some viral dsRNA feeds into
the RNAi pathway and is processed into siRNAs. These
siRNAs may be loaded into RISC, where they guide cleav-
age of single-stranded viral transcripts, thereby adding an-
other level of antiviral activity. However, we observed that
the CYV and DXV VP3 proteins do not only bind long
dsRNA, but also siRNA duplexes. These data suggest that
VP3 does not merely protect the viral genome against Dcr-
2, but that it also scavenges siRNAs to prevent their incor-
poration into RISC. Thus, entomobirnavirus VP3 proteins
counteract multiple aspects of the antiviral RNAi machin-
ery.
Complex interactions may be occurring between
mosquito-specific viruses, pathogenic arboviruses and their
mosquito hosts. For example, induction and suppression of
antiviral pathways by mosquito-specific viruses may affect
the transmission efficiency of co-infecting arboviruses. The
characterization of RNAi antagonists in mosquito-specific
viruses will thus contribute to our understanding of the
factors that influence arbovirus transmission.
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